Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study
Journal of the Endocrine Society · 24.03.2025 · 9 (5)
DOI: 10.1210/jendso/bvaf041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 08.03.2025. Verfasst von Susanna Reincke und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Vosoritide is the first approved targeted therapy for achondroplasia (ACH) based on increased annualized growth velocity in clinical trials. The aim of our project was an assessment of the real-world setting and treatment with vosoritide.
Design
This was a 12-month, retrospective observational study on an inception cohort of 34 patients with ACH treated with vosoritide. Patients and Methods Thirty-four patients with ACH (22 males; aged 2.8 to 15.3 years at treatment initiation) who received vosoritide treatment for at least 12 months at a specialized clinic for skeletal dysplasia in childhood were included in the analysis. Auxological measurements at baseline and after 12 months of therapy were converted into disease-specific (ACH) and general population [Centers for Disease Control and Prevention (CDC)] z-scores. Physical function assessed by a 6-minute walk test was converted into z-scores and compared to an unaffected reference cohort.
Results
After 12 months of treatment, both ACH and CDC height z-scores showed significant increases, with mean changes (mean ± SD) of 0.52 ± 0.35 and 0.38 ± 0.44, respectively (both P < .0001). The annualized growth velocity exceeded reference values for untreated children with ACH. No significant changes were observed in body mass index, upper to lower body segment ratio (sitting height/height), or head circumference. The 6-minute walking distance improved, with z-scores increasing from −2.00 ± 1.12 to −1.39 ± 1.23 (P = .0215).
Conclusion
In a real-world setting, children with ACH showed significant improvements in growth and physical function after 12 months of treatment with vosoritide.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne 50937, Germany.
- Centre for Rare Skeletal Diseases in Childhood, Children's Hospital, University of Cologne, Cologne 50937, Germany.
ORCID-Profile: Oliver Semler, Mirko Rehberg, Heike Hoyer-Kuhn
Zitieren
APA
Reincke, S., Semler, O., Junghänel-Welzing, S., Stasek, S., Rehberg, M., Pfeiffer, E., & Hoyer-Kuhn, H. (2025). Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study. Journal of the Endocrine Society, 9(5). https://doi.org/10.1210/jendso/bvaf041
Vancouver
Reincke S, Semler O, Junghänel-Welzing S, Stasek S, Rehberg M, Pfeiffer E, et al. Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study. Journal of the Endocrine Society. 2025;9(5). doi:10.1210/jendso/bvaf041
BibTeX
@article{Reincke2025,
author = {Reincke, Susanna and Semler, Oliver and Junghänel-Welzing, Shino and Stasek, Stefanie and Rehberg, Mirko and Pfeiffer, Eva and Hoyer-Kuhn, Heike},
title = {Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study},
journal = {Journal of the Endocrine Society},
year = {2025},
volume = {9},
number = {5},
doi = {10.1210/jendso/bvaf041}
}
EUVIMED